Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
28 results
D2.394 - Mycoplasma-Induced Drug Hypersensitivity: Rare Complication or Coincidence?
D2.395 - Erdosteine-induced multifocal fied drug eruption: a case series of five patients
D2.399 - Successful Deferasirox Desensitization in a Patient with Delayed-Type Hypersensitivity
D2.402 - Latex Sensitization as a Risk Factor for Perioperative Hypersensitivity Reactions in Asthmatic Children
D2.403 - When a Topical Drug Goes Systemic: A Case of Dual Hypersensitivity to Diltiazem
D2.405 - UnDRESSing AGEP and Revealing Erythema Multiforme
D2.406 - Severe DRESS in an oncohematological patient: diagnostic and therapeutic challenges
D2.393 - Aspirin hypersensitivity and desensitization-Sense and sensibility
D2.396 - Successful Desensitization in a Patient with a Delayed Type Hypersensitivity Reaction to Ethambutol
D2.397 - Immediate and Delayed Hypersensitivity Reactions to Multiple Thyroid Hormone Preparations: A Challenging Case
D2.398 - Ibuprofen Challenge or Desensitisation in Myo-Pericardial Disease: A Case Series
D2.400 - Vitamin Hypersensitivity in the Era of Intravenous ‘Cocktails’: Diagnostic Pitfalls and Clinical Consequences
D2.545 - Perception of adult patients in an allergy clinic after using Scribe artificial intelligence, our experience
D2.546 - Ethical Impact of Generative AI in Clinical Practice for Asthma and Allergy
D2.547 - The Transparent and Credible AI for Clinical Protocols
D2.548 - Expert Evaluation of Dialogue Quality and Clinical Reasoning in a Hybrid Multilingual LLM–Algorithm Allergy Decision-Support System: A Pilot Study of 34 Real-World Cases
D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download